AKT2 and hepatocellular carcinoma: After treatment of HCC cells with Sorafenib + miR-124-3p.1 inhibitor, the expression of ac-FOXO3a in si-SIRT1 group was significantly higher than that in si-AKT2 group (Fig. 6C).